体部立体定向放疗在寡转移NSCLC的临床应用和前景  

Clinical application and prospect of SBRT in treatment of oligo-metastatic NSCLC

作　　者：方敏[1] 杜向慧[1] 赖霄晶[1] Fang Min;Du Xianghui;Lai Xiaojing(Department of Thoracic Radiotherapy,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院胸部放疗科,中国科学院杭州医学研究所,杭州310022

出　　处：《中华放射肿瘤学杂志》2023年第7期633-637,共5页Chinese Journal of Radiation Oncology

基　　金：国家自然科学基金(81703018);浙江省自然科学基金(LY21H160004);浙江省医药卫生科技计划项目(2020KY466,2022RC110)。

摘　　要：免疫治疗及靶向治疗等药物的快速进展,为局部晚期非小细胞肺癌(NSCLC)带来了长期生存获益。尤其是针对转移病灶少的晚期肺癌,通过积极的局部治疗手段,可进一步提高患者的生存率,甚至达到临床治愈的可能。近年来,随着放射技术的进步,体部立体定向放射治疗(SBRT)实现了对小靶区肿瘤的精准高剂量放射治疗,目前已被广泛应用于不可手术的早期肺癌,而其在晚期肺癌患者中的应用价值和安全性也正被积极探索。本文就SBRT在晚期寡转移肺癌的研究现状、进展及未来发展方向进行讨论。The rapid progress on immunotherapy and targeted therapy has brought long-term survival benefits for locally advanced non-small cell lung cancer(NSCLC).The oncology community has also paid more attention to the local treatment for advanced NSCLC,especially for patients with limited metastatic lesions,also known as oligo-metastasis.Many studies have reported that oligo-metastatic NSCLC patients could benefit from the combination of local and systematic treatment,and even to be cured.In recent years,with the advances in radiation technology,stereotactic body radiation therapy(SBRT)has achieved precise high-dose radiotherapy for small target tumors.Currently,SBRT has been widely applied in the treatment of inoperable early lung cancer,and its application value and safety in patients with advanced lung cancer are also being actively explored.In this article,the research status,progress and future development direction of SBRT in the treatment of oligo-metastatic NSCLC were discussed.

关 键 词：癌 非小细胞肺 寡转移 体部立体定向放射疗法 

分 类 号：R730.55[医药卫生—肿瘤] R734.2[医药卫生—临床医学]